Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Yanbo Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9552-8411; OpenAlex author ID A5027500357. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

  1. IMB5036 inhibits human pancreatic cancer growth primarily through activating necroptosis. First author DOI 10.1111/bcpt.13694↗
  2. DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Co-author DOI 10.1080/15384047.2020.1776580↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qi Zhao · 1 shared paper, 2022 · strength 0.20
  2. Lijun Yang · 1 shared paper, 2022 · strength 0.20
  3. Yi Li · 1 shared paper, 2020 · strength 0.15
  4. Yong‐Su Zhen · 1 shared paper, 2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.